Navigation Links
Key Presentations Announced for Landmark Future of Biosimilars Event Co-Sponsored by DIA and FDLI, Co-Chaired by Merck and PAREXEL

BOSTON, April 28, 2011 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, which serves on the Program Committee for "The Future of Biosimilars in the U.S." conference, today announced distinguishing features of this event, which the Drug Information Association (DIA) will host in cooperation with the Food and Drug Law Institute (FDLI).  The landmark event, to be held May 4 - 5, 2011 in Bethesda, Maryland, will feature perspectives of the U.S. Food and Drug Administration (FDA), as well as industry, lawyers, academics, clinicians, payers and patients on the introduction of biosimilars to the U.S.

This first truly comprehensive conference on biosimilars since the enactment of the Biologics Price Competition and Innovation Act (BPCIA) in 2010 will focus on the critical challenges and current ideas of stakeholders impacted by the development and availability of biological medicines in the U.S.  Featured topics will include industry challenges in developing biosimilars and the need for biosimilars, as well as associated economic and legal considerations. The conference program will feature the following key presentations representing patient, regulatory, and industry viewpoints during the first day of the conference, on Wednesday, May 4:

  • Patience Haydock White, M.D., MA, Chief Public Health Officer of the Arthritis Foundation, the nation's largest national, nonprofit health agency working on behalf of 43 million Americans with doctor diagnosed arthritis and related diseases, will present "Patient Access to High Quality, Safe and Effective Biological Medicines" at 8:25 a.m.

  • Steven Kozlowski, M.D., Director, Office of Biotechnology Products, CDER, FDA, will present "FDA: The Agency's Approach to Biosimilars" at 10:00 a.m.

  • Sandra J.P. Dennis, J.D., Deputy General Counsel of the Biotechnology Industry Organization (BIO), and John Coster, Ph.D., RPh, Senior Vice President for Government Affairs, Generic Pharmaceutical Association, will present "Industry Challenges in Developing Biosimilar Medicinal Products" at 11:15 a.m.

  • Susan C. Winckler, President and CEO of FDLI, and Paul Pomerantz, Worldwide Executive Director of DIA, will provide the welcome and opening remarks for the event.  Program Co-Chair Philip L. Huang, MBA, M.D., Vice President, Vaccine Strategy & Innovation, Merck & Co., Inc., will present the first session of the conference entitled "Overview of Biosimilars:  Patient Access, Challenges, Statutory Framework Enacted as Part of Affordable Care Act."

    According to Alberto Grignolo, Ph.D., Corporate Vice President, Global Strategy and Services, PAREXEL Consulting, and a member of the Program Committee, "Participants will learn about all the significant issues, opportunities and challenges associated with biosimilars development and commercialization in the U.S., including the perspective of the FDA. These learnings will provide the foundation for strategic decisions that companies will need to make, and will no doubt lead to further debates, initiatives, and events as this field continues to evolve."

    To access a podcast with a preview of the key issues that will be discussed at the event, including the viewpoints of Program Co-Chair Cecil J. Nick, B.Sc. (Hons), FTOPRA, Vice President, Technical, PAREXEL Consulting, visit:  More in-depth information about the conference can be found in the article "DIA Teams Up with FDLI for Groundbreaking Biosimilars Conference" published in the DIA Global Forum magazine. To register for "The Future of Biosimilars in the U.S.: Legal, Regulatory, Scientific, Clinical and Payer Issues," visit:

    About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,380 employees. For more information about PAREXEL International visit

    This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.  Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2010 as filed with the SEC on February 9, 2011, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

    PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public Relations

    Kim Baker/Gene CarozzaPAREXEL International

    PAN CommunicationsTel: +781-434-4409

    Tel: + 978-474-1900Email:


    SOURCE PAREXEL International Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ULURU Inc. Announces Commercial Exhibit and Scientific Presentations at the SAWC/WHS National Wound Symposium
    2. HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
    3. WaferGen Announces Data Presentations From Newly Launched High-Throughput SmartChip Human microRNA Panel V2 at Scientific Conferences, Including AACR
    4. Dendreon Announces Webcast Presentations at Upcoming Conferences
    5. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
    6. Idenix Announces Data Presentations at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)
    7. Thoratec Announces Presentations at Upcoming Investor Conferences
    8. Dehaier Medical Announces March Investor Presentations
    9. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
    10. Gen-Probe to Webcast Three Upcoming Investor Presentations
    11. Regeneron Announces March 2011 Investor Conference Presentations
    Post Your Comments:
    (Date:11/26/2015)... 2015 Research and Markets ( ) ... Care Market by Type (Dressings, Therapy Devices, Active Wound ... Out-Patient Facility), and Geography - Global Forecast to 2020" ... --> --> The purpose of this ... of the global advanced wound care market. It involves ...
    (Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
    (Date:11/25/2015)... 2015  The American Academy of Pediatrics (AAP), ... the March of Dimes cheered today,s signature into ... Act of 2015 (S.799), which takes much-needed ... exposed to drugs, such as opioids, and to ... three organizations have worked together leading advocacy efforts ...
    Breaking Medicine Technology:
    (Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Dr. John ... to learn more about hair loss treatment with the Capillus272™ Pro laser therapy cap. ... solution for thicker and fuller hair, without the need for surgery, prescription pills, or ...
    (Date:11/25/2015)... TX (PRWEB) , ... November 25, 2015 , ... For ... the companies’ “ Two Organizations, One Beat ” campaign. The partnership between the two ... services to aid in MAP International’s cause. , MAP International was founded in 1954 ...
    (Date:11/25/2015)... ... 25, 2015 , ... Dental professionals who would like to become more proficient ... attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held ... the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud ...
    (Date:11/25/2015)... , ... November 25, 2015 , ... The McHenry County ... recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. ... Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, ...
    (Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, ... facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion ... at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for ...
    Breaking Medicine News(10 mins):